



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/165,460 10/02/98 RINE

J 0972/006002

REGINALD J. SUYAT  
FISH & RICHARDSON  
2200 SAND HILL ROAD  
SUITE 100  
MENLO PARK CA 94025

HM12/0913

EXAMINER

TUNG, P

ART UNIT	PAPER NUMBER
----------	--------------

1652

11

DATE MAILED:

09/13/00

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

# Office Action Summary

Application No.  
**09/165,460**

Applicant(s)  
**Rine et al.**

Examiner  
**Peter Tung**

Group Art Unit  
**1652**



- ☐ Responsive to communication(s) filed on \_\_\_\_\_.
- ☐ This action is **FINAL**.
- ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claims

- ☒ Claim(s) 10-13, 15, 17-19, and 22-30 is/are pending in the application.
- Of the above, claim(s) 15, 25, 29, and 30 is/are withdrawn from consideration.
- ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- ☒ Claim(s) 10-13, 17-19, 22-24, and 26-28 is/are rejected.
- ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- ☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- ☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

- ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- ☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been
- ☐ received.
- ☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_.
- ☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

- ☒ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

- ☒ Notice of References Cited, PTO-892
- ☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). 5
- ☐ Interview Summary, PTO-413
- ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1652

### DETAILED ACTION

1. Claims 10-13, 15, 17-19, 22-30 are pending.
2. Applicant's election without traverse of Group III, claims 10-13, 17-19, 22-24 and 26-28 in Paper No. 7, dated 4/27/00 is acknowledged.
3. Claims 15, 25, 29 and 30 are withdrawn from further consideration as being drawn to a non-elected invention.

### *Specification*

4. The following CRF errors were corrected by the STIC Systems Branch:  
Sequence 4- moved (ix) FEATURE: id (ii) MOLECULE TYPE: section above (xi) SEQ  
DESCRIPTION heading.

### *Claim Rejections - 35 USC § 112*

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:  

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
6. Claims 10-13, 17-19, 22-24 and 26-28 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for vectors comprising SEQ ID NO: 1 or 2, nucleic acid sequences which encode polypeptides of SEQ ID NO: 3 or 4 or host cells transformed with said vectors, does not reasonably provide enablement for vectors comprising

Art Unit: 1652

nucleic acid sequences which encode polypeptides of SEQ ID NO: 3 or 4 containing conservative substitutions or host cells transformed with said vectors. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. Enablement requires that the specification teach those in the art to make and use the invention without undue experimentation. Factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the relative skill of those in the art, (6) the predictability or unpredictability of the art, and (7) the breadth of the claims. The breadth of the claims encompass a vector encoding either SEQ ID NO: 3 or 4 with any number or conservative amino acid substitutions. While guidance is provided on what amino acids are considered conservative substitutions, insufficient guidance is provided on where conservative amino acid substitutions can be made in the amino acid sequence of SEQ ID NO: 3 or 4 without affecting the function of the protein. Insufficient examples are provided of the proteins comprising SEQ ID NO: 3 or 4 and conservative amino acid substitutions where the proteins still have enzymatic function. The skill of those in the art is low in determining where conservative amino acid substitutions can be made in an enzyme without affecting enzymatic activity as there is unpredictability in the art of making even conservative amino acid substitutions to an enzyme and knowing how such changes will affect

Art Unit: 1652

enzymatic activity. Undue experimentation would be required to enable the full scope of the claims based upon the limiting scope of the disclosure.

7. Claims 11 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for vectors comprising the nucleic acid sequences of SEQ ID NO: 1 or 2, does not reasonably provide enablement for vectors comprising conservatively modified variations of SEQ ID NO: 1 or 2. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. Enablement requires that the specification teach those in the art to make and use the invention without undue experimentation. Factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the relative skill of those in the art, and (6) the breadth of the claims. The breadth of the claim encompasses any number of changes to SEQ ID NO: 1 or 2. Insufficient guidance and insufficient examples are provided on what changes are made to SEQ ID NO: 1 or 2 which would be considered conservative modifications. As the skill of those in the art is low in determining how to use a polynucleotide if it does not encode a particular protein, one of skill in the art would not know how to use such a vector comprising SEQ ID NO: 1 or 2 comprising conservative modifications as the disclosure only teaches SEQ ID NO: 1 and 2 encoding the proteins of SEQ ID NO: 3 and 4, respectively.

Art Unit: 1652

Undue experimentation would be required to enable the full scope of the claims based upon the limiting scope of the disclosure.

8. Claims 11-12, 17-19, 22-24 and 26-28 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The instant claims are drawn to a vector comprising DNA encoding polypeptides of SEQ ID NO: 3 or 4 comprising conservative substitutions and transformed host cells. However, only the polypeptide sequence of SEQ ID NO: 3 and 4 and the DNA sequence of SEQ ID NO: 1 and 2 have been disclosed. The specification and claims do not indicate what distinguishing attributes are shared by the members of the claimed genus of a vector comprising DNA encoding polypeptides of SEQ ID NO: 3 or 4 comprising conservative substitutions. The scope of the claim includes numerous chemical species with widely differing structural, chemical and physical characteristics and the genus is highly variable because a significant number of structural differences between genus members is permitted. The specification and the claims do not provide any guidance as to what is essential to the operation and function of the claimed vector comprising DNA encoding polypeptides of SEQ ID NO: 3 or 4 comprising conservative substitutions and what characteristics could distinguish compounds in the genus from others in the genus are missing from the disclosure. Since the disclosure fails to describe the common attributes or characteristics that identify members of the genus, and because the genus is highly variable, a single disclosed member of the genus is insufficient to describe the

Art Unit: 1652

genus. One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus of a vector comprising DNA encoding polypeptides of SEQ ID NO: 3 or 4 comprising conservative substitutions. *see University of California v. Eli Lilly and Co.* 43 USPQ2d 1398.

9. Claims 26-28 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The cells in claims 26-28 with the specified characteristics must be obtainable by a repeatable method set forth in the specification or otherwise be readily available to the public. If a deposit is made under the terms of the Budapest Treaty, then an affidavit or declaration by applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating that the deposit has been made under the terms of the Budapest Treaty and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent, would satisfy the deposit requirements. *See 37 CFR 1.808.* Further, the record must be clear that the deposit will be maintained in a public depository for a period of 30 years after the date of deposit or 5 years after the last request for a sample **or for the enforceable life of the patent whichever is longer.** *See 37 CFR 1.806.* If the deposit has not been made under the Budapest treaty, then an affidavit or declaration by applicants or someone associated with the patent owner who is in a position to make such

Art Unit: 1652

assurances, or a statement by an attorney of record over his or her signature must be made, stating that the deposit has been made at an acceptable depository and that the criteria set forth in 37 CFR 1.801-1.809, have been met. Applicant's attention is directed to *In re Lundak*, 773 F.2d. 1216, 227 USPQ 90 (CAFC 1985), and 37 CFR 1.801-1.809 for further information concerning deposit practice.

10. Claims 10-12, 17-19, 22-24 and 26-28 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The instant claims are drawn to a polynucleotide or SEQ ID NO: 1 which encodes a polypeptide of SEQ ID NO: 3. However, it does not appear that the polypeptide of SEQ ID NO: 3 is encoded by the polynucleotide of SEQ ID NO: 1. Therefore the Applicant was not in possession of a polynucleotide which encodes the polypeptide of SEQ ID NO: 3.

11. Claims 26-28 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. The instant claims of cells with specific characteristics comprising a polynucleotide which hybridizes to a polynucleotide which encodes SEQ ID NO: 3 or 4 is not supported in the instant specification. The specification does not identify the use of these particular cells as host cells for said polynucleotides.



Art Unit: 1652

***Claim Rejections - 35 USC § 103***

12. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

13. Claims 12, 17, 18, 22 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rose et al. in view of Nozaki et al. (U.S. Patent No. 4,997,767). Rose et al. teach a polynucleotide which is 99.1% identical to a polynucleotide which encodes SEQ ID NO: 3. Such a polynucleotide sequence would be expected to hybridize to a polynucleotide encoding SEQ ID NO: 3 under stringent conditions. Rose et al. do not teach a vector comprising said sequence or host cells comprising said vector. Nozaki et al. teach (Col. 2, lines 45 to Col. 3, line 60) a yeast

Art Unit: 1652

shuttle vector for expressing proteins in yeast which can replicate in both E. coli and in yeast.

Nozaki et al. do not teach a vector comprising a polynucleotide which hybridizes to a polynucleotide encoding SEQ ID NO: 3 or prokaryotic and yeast cells transformed with said vector. It would have been obvious to one of ordinary skill in the art at the time the invention was made to produce vectors, as taught by Nozaki et al., comprising the polynucleotide taught by Rose et al., for the benefit of replicating said vector in E. coli and transforming yeast with said vectors and thereby obtaining yeast for expression of the protein encoded by the DNA taught by Rose et al. One of ordinary skill in the art is motivated to combine the two references as Nozaki et al. teaches a vector for expressing proteins in yeast where the vector can also replicate in E. coli. Rose et al. teach a DNA sequence which encodes a protein where said DNA sequence can be used in the vector taught by Nozaki et al. One of ordinary skill in the art would have a reasonable expectation of success at doing this as the use of shuttle vectors for replicating DNA and expression is well known in the art. Therefore the invention as a whole would have been prima facie obvious to a person of ordinary skill in the art at the time the invention was made.

14. Claim 24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Rose et al. in view of Sambrook et al. Rose et al. teach a polynucleotide which is 99.1% identical to a polynucleotide which encodes SEQ ID NO: 3. Such a polynucleotide sequence would be expected to hybridize to a polynucleotide encoding SEQ ID NO: 3 under stringent conditions. Rose et al. do not teach a vector comprising said sequence or host cells comprising said vector. Sambrook et al. teach (page 16.3-16.6, "Expression of Proteins from Cloned Genes") mammalian cells transformed with

Art Unit: 1652

mammalian expression vectors. Sambrook et al. do not teach a vector comprising a polynucleotide which hybridizes to a polynucleotide encoding SEQ ID NO: 3 or mammalian cells comprising said vector. A mammalian cell comprising a vector, as taught by Sambrook et al., comprising a polynucleotide which hybridizes to a polynucleotide encoding SEQ ID NO: 3, as taught by Rose et al., would have been obvious to one of ordinary skill in the art at the time the invention was made. One of ordinary skill in the art is motivated to combine the two references as Sambrook et al. teach mammalian cells transformed with an expression vector for producing proteins and Rose et al. teach a DNA sequence which encodes a protein where said DNA sequence can be used in the expression vector taught by Sambrook et al. One of ordinary skill in the art would have a reasonable expectation of success at doing this as expressing proteins in mammalian cells is well known in the art. Therefore the invention as a whole would have been prima facie obvious to a person of ordinary skill in the art at the time the invention was made.


15. No claims are allowed.

16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter Tung, Ph.D. whose telephone number is (703) 308-9436. The examiner can normally be reached on Monday-Friday from 9:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy, Ph.D., can be reached on (703) 308-3804. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-0294.

Art Unit: 1652

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



PONNATHAPU ACHUTAMURTHY  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

## seq\_documentation\_block:

LOCUS SCYJR117W 1825 bp DNA PLN 11-AUG-1997  
DEFINITION S.cerevisiae chromosome X reading frame ORF YJR117w.  
ACCESSION Z49617 Y13136  
VERSION Z49617.1 GI:1015836  
KEYWORDS .  
SOURCE baker's yeast.  
ORGANISM Saccharomyces cerevisiae  
Eukaryota; Fungi; Ascomycota; Hemiascomycetes; Saccharomycetales;  
Saccharomycetaceae; Saccharomyces.  
REFERENCE 1 (bases 1 to 1825)  
AUTHORS Rose, M., Koetter, P. and Entian, K.D.  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 1825)  
AUTHORS MIPS.  
TITLE Direct Submission  
JOURNAL Submitted (25-SEP-1995) Data collected by MIPS on behalf of the  
European yeast chromosome X sequencing project. MIPS at the  
Max-Planck-Institut fuer Biochemie, Am Klopferspitz 18a D-82152  
Martinsried, FRG; E-mail: Mewes@mips.embnnet.org

FEATURES Location/Qualifiers  
source 1. .1825  
/organism="Saccharomyces cerevisiae"  
/db\_xref="taxon:4932"  
/chromosome="X"  
gene 343. .1704  
/gene="STE24"  
CDS 343. .1704  
/gene="STE24"  
/note="ORF YJR117w"  
/codon\_start=1  
/protein\_id="CAA89647.1"  
/db\_xref="GI:1015837"  
/db\_xref="SWISS-PROT:P47154"

/translation="MFDLKTILDHPNIPWKLIISGFSIAQFSFESYLYRQYQKLSET  
KLPPVLEDEIDDETFHKSRNYSRAKAKFSIFGDVYNLAQKLVIKYDLFPKIWHMAVS  
LLNAVLPVRFHMVSTVAQSLCFLGLSSSLSTLVDLPLSYSHFVLEEKFGFNKLTVQL  
WITDMIKSLTLAYAIGGPILYLFLKIFDKFPTDFLWYIMVFLFVVQILAMTIIPVFIM  
PMFNKFTPLEDGELKKSIESLADRVGFPLDKIFVIDGSKRSSHSNAYFTGLPFTSKRI  
VLFDTLVNSNSTDEITAVLAHEIGHWQKNHIVNMVIFSQ LHTFLIFS LFTSIYRNTSF  
YNTFGFFLEKSTGSFVDPVITKEFP I IIGFMLFNDLLTPLECAMQFVMSLISRTHEYQ  
ADAYAKKLGYKQNLCRALIDLQIKNLSTMNVDPYSSYHYSHPTLAERLTALDYVSEK  
KKN"

BASE COUNT 570 a 397 c 280 g 578 t  
ORIGIN

## alignment\_scores:

Quality: 2294.50

Length: 451

Ratio: 5.133 Gaps: 1  
Percent Similarity: 99.113 Percent Identity: 99.113

alignment\_block:

US-09-165-460-3 x SCYJR117W ..

Align seg 1/1 to: SCYJR117W from: 1 to: 1825

```
1 MetPheAspLeuLysThrIleLeuAspHisProAsnThrProTrpLysLe 17
|||||
343 ATGTTTGATCTTAAGACGATTCTCGACCATCCTAATATCCCGTGGAAATT 392

17 uIleIleSerGlyPheSerIleAlaGlnPheSerPheGluSerTyrLeuT 34
|||||
393 AATCATTTCTGGGTCTCGATTGCCCAATTTCTTTCGAATCTTACTTGA 442

34 hrTyrArgGlnTyrGlnLysLeuSerGluThrLysLeuProProValLeu 50
|||||
443 CGTACAGACAGTACCAGAAGCTATCTGAAACAAAGTTGCCACCTGTGCTG 492

51 GluAspGluIleAspAspGluThrPheHisLysSerArgAsnTyrSerAr 67
|||||
493 GAAGACGAAATTGATGATGAACTTTTCATAAATCAAGGAACTACTCCCG 542

67 gAlaLysAlaLysPheSerIlePheGlyAspValTyrAsnLeuAlaGlnL 84
|||||
543 GGCCAAAGGCCAAGTTCTCCATTTTCGGTGACGTCTATAACCTAGCCCAAA 592

84 ysLeuValPheIleLysTyrAspLeuPheProLysIleTrpHisMetAla 100
|||||
593 AGCTAGTTTTCATCAAATACGACCTCTTCCCTAAATCTGGCACATGGCC 642

101 ValSerLeuLeuAsnAlaValLeuProValArgPheHisMetValSerTh 117
|||||
643 GTTTCTTTATTGAATGCAGTCCTGCCAGTCAGATTTTCATATGGTCTCCAC 692

117 rValAlaGlnSerLeuCysPheLeuGlyLeuLeuSerSerLeuSerThrL 134
|||||
693 TGTCGCACAGAGTTTATGCTTCTTGGGTCTCTTATCCAGTTTGTCTACCT 742

134 euValAspLeuProLeuSerTyrTyrSerHisPheValLeuGluGluLys 150
|||||
743 TGGTTGATTTGCCACTCTCTTACTATAGCCATTTTGTCTGGAAGAAAAA 792

151 PheGlyPheAsnLysLeuThrValGlnLeuTrpIleThrAspMetIleLy 167
|||||
793 TTTGGTTTCAATAAATTGACCGTCCAATATGGATCACCGATATGATCAA 842

167 sSerLeuThrLeuAlaTyrAlaIleGlyGlyProIleLeuTyrLeuPheL 184
|||||
843 GAGTCTGACTTTGGCGTATGCTATTGGTGGCCCAATCCTTTACCTGTTCC 892

184 euLysIlePheAspLysPheProThrAspPheLeuTrpTyrIleMetVal 200
|||||
893 TTAAGATCTTTGATAAATTCCTACTGATTTTCTTTGGTACATTATGGTC 942

201 PheLeuPheValValGlnIleLeuAlaMetThrIleIleProValPheIl 217
```

943 TTCTTGTTTCGTTGTCCAAATCTTAGCCATGACAATCATTCCAGTCTTCAT 992  
 217 eMetProMetPheMetLysPheThrProLeuGluAspGlyGluLeuLysL 234  
 993 CATGCCCATGTTTAATAAGTTCACCTCATTGGAGGACGGTGAAGTGA AAA 1042  
 234 ysSerIleGluSerLeuAlaAspArgValGlyPheProLeuAspLysIle 250  
 1043 AATCTATTGAAAGTTTGGCCGATAGAGTTGGGTTCCCTCTAGATAAGATT 1092  
 251 PheValIleAspGlySerLysArgSerSerHisSerAsnAlaTyrPheTh 267  
 1093 TTTGTTCATTGACGGCTCAAAAAGATCTTCTCATTCAAACGCATATTTTAC 1142  
 267 rGlyLeuProPheThrSerLysArgIleValLeuPheAspThrLeuValA 284  
 1143 AGGTTTGCCATTACCTCCAAGAGAATTGTTTTGTTTCGACACTTTAGTGA 1192  
 284 snSerAsnSerThrAspGluIleThrAlaValLeuAlaHisGluIleGly 300  
 1193 ACAGTAATTCTACTGATGAAATTACGGCTGTTTTGGCCCATGAAATCGGT 1242  
 301 HisTrpGlnLysMetHisIleValAsnMetValIlePheSerGlnLeuHi 317  
 1243 CACTGGCAAAAAACCACATCGTTAATATGGTCATCTTTAGTCAATTGCA 1292  
 317 sThrPheLeuIlePheSerLeuPheThrSerIleTyrArgAsnThrSerP 334  
 1293 CACCTTCCTCATTTTCTCCCTTTTACCAGCATCTACAGAAATACATCAT 1342  
 334 heTyrAsnThrPheGlyPhePheLeuGluLysSerThrGlySerSerPhe 350  
 1343 TTTACAACACCTTCGGCTTTTTCTTAGAGAAGTCCACTGGC...AGTTTT 1389  
 351 ValAspProValIleThrLysGluPheProIleIleIleGlyPheMetLe 367  
 1390 GTTGATCCCGTTATCACTAAGGAATTCCCATTTATCATTGGATTTATGTT 1439  
 367 uPheAsnAspLeuLeuThrProLeuGluCysAlaMetGlnPheValMetS 384  
 1440 ATTTAACGACTTATTAACCTCCACTCGAATGTGCCATGCAATTCGTGATGA 1489  
 384 erLeuIleSerArgThrHisGluTyrGlnAlaAspAlaTyrAlaLysLys 400  
 1490 GTTTAATTTCCAGAACTCATGAATATCAAGCTGATGCTTATGCTAAAAAA 1539  
 401 LeuGlyTyrLysGlnAsnLeuCysArgAlaLeuIleAspLeuGlnIleLy 417  
 1540 TTGGGCTACAAGCAAAATCTATGTAGGGCTCTAATTGATCTACAAATCAA 1589  
 417 sAsnLeuSerThrMetAsnValAspProLeuTyrSerSerTyrHisTyrS 434  
 1590 AAACCTTTCCACCATGAATGTAGATCCTCTGTATTCTAGCTATCATTATT 1639  
 434 erHisProThrLeuAlaGluArgLeuThrAlaLeuAspTyrValSerGlu 450

1640 CCCATCCAACCTCTAGCTGAAAGATTGACCGCTCTAGACTATGTTAGTGAA 1689

451 Lys 451

|||

1690 AAG 1692



RESULT 1  
 SCYJR117W  
 LOCUS SCYJR117W 1825 bp DNA PLN 11-AUG-1997  
 DEFINITION S.cerevisiae chromosome X reading frame ORF YJR117w.  
 ACCESSION Z49617 Y13136  
 VERSION Z49617.1 GI:1015836  
 KEYWORDS  
 SOURCE baker's yeast.  
 ORGANISM Saccharomyces cerevisiae  
 Eukaryota; Fungi; Ascomycota; Hemiascomycetes; Saccharomycetales;  
 Saccharomycetaceae; Saccharomyces.  
 REFERENCE 1 (bases 1 to 1825)  
 AUTHORS Rose,M., Koetter,P. and Entian,K.D.  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 1825)  
 AUTHORS MIPS.  
 TITLE Direct Submission  
 JOURNAL Submitted (25-SEP-1995) Data collected by MIPS on behalf of the  
 European yeast chromosome X sequencing project. MIPS at the  
 Max-Planck-Institut fuer Biochemie, Am Klopferspitz 18a D-82152  
 Martinsried, FRG; E-mail: Mewes@mips.embnet.org  
 FEATURES Location/Qualifiers  
 source 1..1825  
 /organism="Saccharomyces cerevisiae"  
 /db\_xref="taxon:4932"  
 /chromosome="X"  
 gene 343..1704  
 /gene="STE24"  
 CDS 343..1704  
 /gene="STE24"  
 /note="ORF YJR117w"  
 /codon\_start=1  
 /protein\_id="CAA89647.1"  
 /db\_xref="GI:1015837"  
 /db\_xref="SWISS-PROT:P47154"  
 /translation="MFDLKTILDHPNIPWKLIISGFSIAQFSFESYLTYRQYQKLSET  
 KLPPVLEDEIDDETFHKSRNYSRAKAKFSIFGDVYNLAQKLVFIFYDLFPKIWHMAVS  
 LLNAVLPVRFHMVSTVAQSLCFLGLLSSLSTLVDLPLSYSHFVLEEKFGFNKLTQVL  
 WITDMLKSLTLAYAIGGPILYFLKIFDKFPTDFLWYIMVFLFVVQILAMTIIPVFIM  
 PMFNKFTPLEDGELKKSIESLADRVGFPLDKIFVIDGSKRSSHSNAYFTGLPFTSKRI  
 VLFDTLVNSNSTDEITAVLAHEIGHWQKNHIVNMVIFSQ LHTFLIFSLFTSIYRNTSF  
 YNTFGFFLEKSTGSFVDPVITKEFPPIIIGFMLFNDLLTPLECAMQFVMSLISRTHEYQ  
 ADAYAKKLGKYNLCRALIDLQIKNLSTMNVDPYSSYHYSHPTLAERLTALDYVSEK  
 KKN"  
 BASE COUNT 570 a 397 c 280 g 578 t  
 ORIGIN

Query Match 98.7%; Score 1800.4; DB 7; Length 1825;

Best Local Similarity 99.8%; Pred. No. 0;  
Matches 1823; Conservative 0; Mismatches 1; Indels 2; Gaps  
2;

```
Qy      1 ACCTACCTTTTTTCTATCTTCAACAACGAAACGCCTTACACACACACACACATACATCT 60
      |||
Db      1 ACCTACCTTTTTTCTATCTTCAACAACGAAACGCCTTACACACACACACACATACATCT 60

Qy     61 ACATACATACATACAAATATACATATATGTAACTTGTATATTCATTCCTATTAACCAA 120
      |||
Db     61 ACATACATACATACAAATATACATATATGTAACTTGTATATTCATTCCTATTAACCAA 120

Qy    121 AAGAGGCAATTAAACTTTTCCCTCTTTTCTACGTCATTTACTCAAAAACCTCTAATTCCT 180
      |||
Db    121 AAGAGGCAATTAAACTTTTCCCTCTTTTCTACGTCATTTACTCAAAAACCTCTAATTCCT 180

Qy    181 TCGTCTCTGTTCTGCCATTTTCTCCAGAAAAAATCGACGGGAAATAAAAAAAAAAAGAC 240
      |||
Db    181 TCGTCTCTGTTCTGCCATTTTCTCCAGAAAAAATCGACGGGAAATAAAAAAAAAAAGAC 240

Qy    241 AACGAACAAGAGAAAAAGTTCGCGAATTATAAACCACCTTCTATAATTAACAGGAAAAGGA 300
      |||
Db    241 AACGAACAAGAGAAAAAGTTCGCGAATTATAAACCACCTTCTATAATTAACAGGAAAAGGA 300

Qy    301 AGGAAAAAAAAAGGAGGAAA-AGAAACTGCAGGCCTTTATTCATGTTTGATCTTAAGACG 359
      |||
Db    301 AGGAAAAAAAAAGGAGGAAATAGAAACTGCAGGCCTTTATTCATGTTTGATCTTAAGACG 360

Qy    360 ATTCTCGACCATCCTAATATCCCGTGGAATTAATCATTTCTGGGTTCTCGATTGCCCAA 419
      |||
Db    361 ATTCTCGACCATCCTAATATCCCGTGGAATTAATCATTTCTGGGTTCTCGATTGCCCAA 420

Qy    420 TTTTCTTTTGAATCTTACTTGACGTACAGACAGTACCAGAAGCTATCTGAAACAAAGTTG 479
      |||
Db    421 TTTTCTTTTGAATCTTACTTGACGTACAGACAGTACCAGAAGCTATCTGAAACAAAGTTG 480

Qy    480 CCACCTGTGCTGGAAGACGAAATTGATGATGAAACTTTTCATAAATCAAGGAACTACTCC 539
      |||
Db    481 CCACCTGTGCTGGAAGACGAAATTGATGATGAAACTTTTCATAAATCAAGGAACTACTCC 540

Qy    540 CGGGCCAAGGCCAAGTTCTCCATTTTCGGTGACGTCTATAACCTAGCCCAAAGCTAGTT 599
      |||
Db    541 CGGGCCAAGGCCAAGTTCTCCATTTTCGGTGACGTCTATAACCTAGCCCAAAGCTAGTT 600

Qy    600 TTCATCAAATACGACCTCTTCCCTAAAATCTGGCACATGGCCGTTTCTTTATTGAATGCA 659
      |||
Db    601 TTCATCAAATACGACCTCTTCCCTAAAATCTGGCACATGGCCGTTTCTTTATTGAATGCA 660

Qy    660 GTCCTGCCAGTCAGATTTTCATATGGTCTCCACTGTCGCACAGAGTTTATGCTTCTTGGG 719
      |||
Db    661 GTCCTGCCAGTCAGATTTTCATATGGTCTCCACTGTCGCACAGAG-TTTATGCTTCTTGGG 719

Qy    720 TCTCTTATCCAGTTTGTCTACCTTGGTTGATTTGCCACTCTCTTACTATAGCCATTTTGT 779
      |||
Db    720 TCTCTTATCCAGTTTGTCTACCTTGGTTGATTTGCCACTCTCTTACTATAGCCATTTTGT 779

Qy    780 CCTGGAAGAAAAATTTGGTTTCAATAAATTGACCGTCCAACCTATGGATCACCGATATGAT 839
```

Db	780	 CCTGGAAGAAAAATTTGGTTTCAATAAATTGACCGTCCAACATGGATCACCGATATGAT	839
Qy	840	CAAGAGTCTGACTTTGGCGTATGCTATTGGTGGCCCAATCCTTTACCTGTTCTTAAGAT	899
Db	840	 CAAGAGTCTGACTTTGGCGTATGCTATTGGTGGCCCAATCCTTTACCTGTTCTTAAGAT	899
Qy	900	CTTTGATAAATTCCTACTGATTTCTTTGGTACATTATGGTCTTCTTGTTTCGTTGTCCA	959
Db	900	 CTTTGATAAATTCCTACTGATTTCTTTGGTACATTATGGTCTTCTTGTTTCGTTGTCCA	959
Qy	960	AATCTTAGCCATGACAATCATTCCAGTCTTCATCATGCCCATGTTTAATAAGTTCACTCC	1019
Db	960	 AATCTTAGCCATGACAATCATTCCAGTCTTCATCATGCCCATGTTTAATAAGTTCACTCC	1019
Qy	1020	ATTGGAGGACGGTGAACCTGAAAAAATCTATTGAAAGTTTGGCCGATAGAGTTGGGTTCCC	1079
Db	1020	 ATTGGAGGACGGTGAACCTGAAAAAATCTATTGAAAGTTTGGCCGATAGAGTTGGGTTCCC	1079
Qy	1080	TCTAGATAAGATTTTTGTCAATTGACGGCTCAAAAAGATCTTCTCATTCAAACGCATATTT	1139
Db	1080	 TCTAGATAAGATTTTTGTCAATTGACGGCTCAAAAAGATCTTCTCATTCAAACGCATATTT	1139
Qy	1140	CACAGGTTTGCCATTACCTCCAAGAGAATTGTTTTGTTTCGACACTTTAGTGAACAGTAA	1199
Db	1140	 CACAGGTTTGCCATTACCTCCAAGAGAATTGTTTTGTTTCGACACTTTAGTGAACAGTAA	1199
Qy	1200	TTCTACTGATGAAATTACGGCTGTTTTGGCCCATGAAATCGGTCACTGGCAAAAAAACCA	1259
Db	1200	 TTCTACTGATGAAATTACGGCTGTTTTGGCCCATGAAATCGGTCACTGGCAAAAAAACCA	1259
Qy	1260	CATCGTTAATATGGTCATCTTTAGTCAATTGCACACCTTCCTCATTTTCTCCCTTTTCAC	1319
Db	1260	 CATCGTTAATATGGTCATCTTTAGTCAATTGCACACCTTCCTCATTTTCTCCCTTTTCAC	1319
Qy	1320	CAGCATCTACAGAAATACATCATTTTACAACACCTTCGGCTTTTCTTAGAGAAGTCCAC	1379
Db	1320	 CAGCATCTACAGAAATACATCATTTTACAACACCTTCGGCTTTTCTTAGAGAAGTCCAC	1379
Qy	1380	TGGCAGTTTTGTTGATCCCGTTATCACTAAGGAATTCCCCATTATCATTGGATTTATGTT	1439
Db	1380	 TGGCAGTTTTGTTGATCCCGTTATCACTAAGGAATTCCCCATTATCATTGGATTTATGTT	1439
Qy	1440	ATTTAACGACTTATTAACCTCACTCGAATGTGCCATGCAATTCGTGATGAGTTTAATTC	1499
Db	1440	 ATTTAACGACTTATTAACCTCACTCGAATGTGCCATGCAATTCGTGATGAGTTTAATTC	1499
Qy	1500	CAGAACTCATGAATATCAAGCTGATGCTTATGCTAAAAAATTGGGCTACAAGCAAAATCT	1559
Db	1500	 CAGAACTCATGAATATCAAGCTGATGCTTATGCTAAAAAATTGGGCTACAAGCAAAATCT	1559
Qy	1560	ATGTAGGGCTCTAATTGATCTACAAATCAAAAACCTTTCCACCATGAATGTAGATCCTCT	1619
Db	1560	 ATGTAGGGCTCTAATTGATCTACAAATCAAAAACCTTTCCACCATGAATGTAGATCCTCT	1619
Qy	1620	GTATTCTAGCTATCATTATTCCCATCCAACCTCTAGCTGAAAGATCGACCGCTCTAGACTA	1679

Db 1620 GTATTCTAGCTATCATTATTCCCATCCAACCTAGCTGAAAGATTGACCGCTCTAGACTA 1679

Qy 1680 TGT TAGTGAAAAGAAGAAAACTAATCTATAGAGTACACATATTAGCATGTACCGTTAAA 1739  
|||||

Db 1680 TGT TAGTGAAAAGAAGAAAACTAATCTATAGAGTACACATATTAGCATGTACCGTTAAA 1739

Qy 1740 TTCAGCTTCGTTATGTCTATATCTACATACATACACAGGTATCTACTATAAGAATAAAGG 1799  
|||||

Db 1740 TTCAGCTTCGTTATGTCTATATCTACATACATACACAGGTATCTACTATAAGAATAAAGG 1799

Qy 1800 AAAGAAAAAATAAACGATTAAACATT 1825  
|||||

Db 1800 AAAGAAAAAATAAACGATTAAACATT 1825